10-Q: Village Farms International Reports Strong Revenue Growth

Village Farms International, Inc. announced a 7% increase in consolidated revenues for the second quarter of 2026, driven by significant growth in international cannabis exports and improved gross margins.

Summary

• Village Farms International, Inc. reported a 7% increase in consolidated revenue for the three months ended June 30, 2026, reaching $63.98 million, up from $59.90 million in the prior year period.
• For the six months ended June 30, 2026, revenue increased by 15% to $114.22 million, compared to $99.58 million in the same period last year.
• Net income attributable to shareholders for the three months ended June 30, 2026, was $7.15 million ($0.06 per share), a decrease from $26.50 million ($0.24 per share) in the prior year, largely due to the absence of income from discontinued operations.
• For the six months ended June 30, 2026, net income attributable to shareholders was $10.06 million ($0.09 per share), down from $19.79 million ($0.18 per share) in the prior year, also impacted by discontinued operations.
• The company's cannabis segment is now its sole reportable segment, with 'Other' comprising its remaining operations.
• International export sales saw a significant increase of 74% year-over-year for the quarter, reaching $20.9 million, and a 104% increase for the six-month period, reaching $35.5 million.
• Gross margin improved to 47% for the quarter, up from 37% in the prior year, and to 45% for the six-month period, up from 37% in the prior year.
• The company closed a registered direct offering on June 8, 2026, raising approximately $15 million for working capital and general corporate purposes.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting solid revenue growth driven by international expansion and improved gross margins, despite some segment-specific headwinds.

Positives

• Consolidated revenue increased by 7% to $63.98 million for Q2 2026 and by 15% to $114.22 million for the first six months of 2026.
• International export sales surged by 74% year-over-year in Q2 2026 to a record $20.9 million, and by 104% for the first six months.
• Gross margin improved significantly to 47% in Q2 2026 from 37% in Q2 2025, and to 45% for the first six months from 37% in the prior year.
• The company maintained its top five overall market share position in Canada and expanded market share in vapes and infused pre-rolls.
• Record production was achieved from Delta, British Columbia facilities in the first half of 2026, with increased yields and operating efficiencies leading to lower production costs.
• Cultivation commenced at the Phase II facility in Groningen, Netherlands, expected to increase annual production capacity to approximately 10 metric tonnes.
• The company is accelerating technology upgrades for the Delta 2 greenhouse expansion, which is expected to yield approximately 15 metric tonnes in the second half of 2026 and reach full capacity of 40 metric tonnes by mid-2027.
• Raised approximately $15 million in gross proceeds from a registered direct offering on June 8, 2026, for working capital and general corporate purposes.

Negatives

• Net income attributable to shareholders decreased significantly in both the three-month and six-month periods ended June 30, 2026, primarily due to the absence of income from discontinued operations in the current year's reporting.
• U.S. Cannabis sales decreased by 16% for the quarter due to market saturation from unregulated hemp-derived products and evolving state regulations.
• Canadian Branded sales decreased by 8% for the quarter, primarily due to a decrease in volume of value brands.
• Canadian Non-Branded sales decreased by 57% for the quarter due to a shift in volume towards International Exports.
• Selling, general and administrative expenses increased by 24% for the quarter, primarily due to higher commercial and marketing expenses and an update to transfer pricing policies.
• The company incurred $14.9 million in excise duties for Q2 2026, representing 39% of gross Canadian Branded sales, which is noted as a significant cost.

Risks

• Uncertainty regarding the legality and regulatory status of cannabis and cannabinoid (CBD) products in the United States.
• Risks related to the implementation and enforcement of new legislation that may affect the CBD business in the United States.
• Potential difficulties in achieving and/or maintaining profitability.
• Variability of product pricing in the cannabis and agricultural markets.
• Risks inherent in the cannabis, hemp, CBD, cannabinoids, and agricultural businesses.
• Market position and competitive pressures.
• Ability to leverage current business relationships for future hemp and cannabinoid business.
• Potential difficulties in managing growth and international expansion.

Future Outlook

The company expects its existing cash, cash generated from operations, and availability under its revolving credit facility to provide sufficient liquidity for the next 12 months, covering working capital needs, debt repayments, and planned capital expenditures. Additional liquidity may be sought through capital markets.

Management Comments

• "Our focus for Cannabis is to produce high quality cannabis, leveraging our low-cost production to provide preferred products at an attractive price that address the preferred consumer segments in the market."
• "As a result of the typically higher margins in international markets (predominantly due to lower taxation compared with Canada), we expect international expansion to enhance our profitability while expanding our brand and experience into emerging legal cannabis markets."
• "The Company believes it remains the largest exporter of medical cannabis to Europe with a leading market share position in Germany."
• "The Company commenced cultivation at its Phase II facility in Groningen, Netherlands during Q2. The Groningen facility will bring the Company's maximum annualized production capacity in the Netherlands to approximately 10 metric tonnes and is expected to ramp to full production into early 2027."
• "During Q2 the Company harvested its first crop from the first half of its Delta 2 greenhouse expansion, and announced that it is accelerating technology upgrades quicker than previously anticipated due to increasing global demand."

Industry Context

StockSavvy.ai notes that Village Farms International's strategic shift to a unified cannabis operating model aligns with industry consolidation trends. The significant growth in international exports, particularly to Europe, reflects the global expansion of legal cannabis markets and the company's ability to leverage its EU GMP certification. The challenges in the U.S. market due to unregulated products highlight the ongoing regulatory complexities in that region.

Comparison to Industry Standards

• The company's gross margin of 47% for Q2 2026 is strong, especially within the competitive cannabis industry where margins can be volatile.
• International export sales growth of 74% year-over-year for Q2 2026 significantly outpaces the average growth rates seen in many mature cannabis markets.
• The company's position as a leading exporter of medical cannabis to Europe, with a leading market share in Germany, suggests it is performing well against other international suppliers.
• The focus on low-cost production and high-quality cannabis aligns with industry best practices for achieving sustainable profitability.
• The company's ability to achieve record production and improve operating efficiencies at its Delta facilities demonstrates effective operational management, a key differentiator in the industry.

Management Changes

Legal Proceedings

• The company is engaged in legal proceedings in the ordinary course of business, but does not believe any current proceedings will have a material impact on its business.

Related Party Transactions

• The company leases its Rose office building from a former employee who also owns a minority interest in Rose.
• A Transition Services Agreement and a Sales, Marketing & Distribution Agreement are in place with Village Fresh, a Verdexa subsidiary, for produce operations.

Stakeholder Impact

• Shareholders: The registered direct offering may dilute existing shareholders, but the capital raised is intended for working capital and general corporate purposes, potentially supporting future growth.
• Employees: Increased production and operational efficiencies may lead to stable or increased employment opportunities.
• Customers: Continued focus on high-quality cannabis and international expansion aims to meet diverse market demands.
• Suppliers: The company's operational growth and international reach may create opportunities for suppliers.

Next Steps

• Ramp up production at the Groningen, Netherlands facility to full capacity by early 2027.
• Achieve full production capacity of 40 metric tonnes annually from the Delta 2 expansion by mid-2027.
• Continue to leverage international expansion to enhance profitability and enter emerging legal cannabis markets.
• Utilize proceeds from the recent offering for working capital and general corporate purposes.

Key Dates

Recommendation

The company demonstrates strong operational execution with revenue growth and margin expansion in its core cannabis business, particularly in international markets. However, the decrease in net income due to discontinued operations, coupled with ongoing challenges in the U.S. market and significant excise taxes in Canada, warrants a cautious approach. The recent capital raise provides liquidity but also introduces dilution. A 'hold' recommendation reflects the balance between positive operational trends and existing market/financial uncertainties.

Keywords

Cannabis, International Exports, Gross Margin, Revenue Growth, Netherlands, Germany, Produce, Clean Energy